Clinical Trials Logo

Filter by:
NCT ID: NCT01453777 Withdrawn - Clinical trials for Brain Lesion (General)

Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain

Start date: May 2011
Phase: N/A
Study type: Interventional

The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with diffuse brain lesions and clinical outcomes.

NCT ID: NCT01408342 Withdrawn - Aplastic Anemia Clinical Trials

Alemtuzumab and Rituximab in Aplastic Anemia

Start date: July 2011
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

NCT ID: NCT00989274 Withdrawn - Influenza Clinical Trials

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Start date: June 2010
Phase: Phase 2
Study type: Interventional

In agreement with the World Organization of the Health (WHO), during the annual epidemics of influenza they become infected between 10-20 % of the total population, appearing from a feverish disease up to leading to the hospitalization and in some cases to the death. To unpredictable intervals and due to the nature of the virus, this one can acquire new genes of others virus of the influenza that they concern birds or porks, of it it turns out to be a new virus with a completely new subtype of IT (HE,SHE) HAS and NA, and if this one is transmitted efficiently of person-to-person can cause a pandemic. This phenomenon has been the one that has given place to the appearance of a new causative virus of the outbreak of influenza humanizes in Mexico (A/México/2009 (H1N1)), and in agreement to official Mexican numbers(figures), until August 13 there have been brought(reported) a whole of 18,861 cases and 163 deaths. The measure of the most effective control against the influenza constitutes it the vaccine, by what study becomes imperative to possess (to rely on) a vaccine against the new virus To (H1N1) East is relevant, due to the level of response of alert to a level 6 (pandemic) that has passed the World Organization of the Health (WHO).

NCT ID: NCT00930189 Withdrawn - Clinical trials for Subfoveal Choroidal Neovascularization

Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization

Start date: April 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of photodynamic therapy with verteporfin (PDT) and IVTA vs triple therapy (TT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The investigators designed a prospective, comparative, randomized, double blind, controlled study. 15 patients with classic subfoveal choroidal neovascularization secondary to age-related macular degeneration were randomized. Triple therapy can potentially offer a new treatment modality for choroidal neovascularization in patients with macular degeneration and other diseases.

NCT ID: NCT00875875 Withdrawn - Travelers' Diarrhea Clinical Trials

Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea

Rifaximin 600
Start date: June 2009
Phase: Phase 4
Study type: Interventional

The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR 2. a single 600 mg dose of rifaximin daily for 3 days.

NCT ID: NCT00804869 Withdrawn - Axial Length (AL) Clinical Trials

A-mode vs PalmScan Ultrasonography: Biometric Measurements.

Start date: October 2008
Phase:
Study type: Observational

Ultrasonography has become a critical ancillary test in the clinical practice of ophthalmology. It is commonly used as a standardized method for assessing intraocular biometry. The PalmScan ultrasonography (PsU) is a portable A-scan device that uses the same principles as the standard A-scan. The aim of the study is to compare the reliability of their measurements, in order to use them indistinctively.

NCT ID: NCT00803153 Withdrawn - Clinical trials for Choroidal Detachment

PASCAL: Safety and Complications, Experience After 1301 Consecutive Cases

Start date: December 2008
Phase:
Study type: Observational

To report the safety and incidence of adverse effects, during and after a successful photocoagulation for different pathologies using a Pattern Scan Laser (PASCAL) system and its modified settings

NCT ID: NCT00801866 Withdrawn - Macular Edema Clinical Trials

Avastin for Post-photocoagulation Macular Edema

Start date: December 2008
Phase: Phase 4
Study type: Interventional

to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

NCT ID: NCT00760916 Withdrawn - Clinical trials for Pulmonary Hypertension

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor)or as a monotherapy treatment. Study visits will occur at 4 week intervals for 12 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. At the end of the first 12-weeks, the patient will be un-blinded. Patients will continue with another 12-Week open label portion with visits occuring at 4-week intervals. Patients who complete all assessments for 24-weeks will also be eligible to enter a 36 month open-label, extension phase study (FREEDOM - EXT).

NCT ID: NCT00760032 Withdrawn - Cirrhosis Clinical Trials

Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients

Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether plasma levels of lipopolysaccharide binding protein (LBP) are correlated with PBMN pro- and anti-inflammatory cytokine secretion, as well as with the development of severe infectious events in cirrhotic patients with ascites. As a secondary purpose, the study will evaluate the effect of a prophylactic administration of ciprofloxacin on LBP, cytokines and infections in the same patients.